<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Myopericarditis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Myopericarditis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Myopericarditis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Massimo Imazio, MD, FESC, FHFA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Myopericarditis, a complication of acute pericarditis, is characterized by extension of pericardial inflammation to the myocardium, which can manifest as an elevated troponin level and electrocardiogram (ECG) changes (mainly ST-segment elevation). It is generally evaluated and treated as acute pericarditis. The key challenge in managing myopericarditis is excluding the presence of an acute coronary syndrome  (<a class="graphic graphic_algorithm graphicRef132075" href="/z/d/graphic/132075.html" rel="external">algorithm 1</a>).</p><p>Perimyocarditis also presents as acute pericarditis, but it is characterized by a decrease in left ventricular (LV) function; it should be evaluated as myocarditis and, if present, treated as myocarditis.</p><p>The clinical presentation, diagnostic evaluation, and treatment for myopericarditis will be reviewed here. The etiology, treatment, and prognosis of acute pericarditis, other pericardial diseases, and myocarditis are discussed separately. Myocardial injury related to coronavirus disease 2019 is also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4957.html" rel="external">"Etiology of pericardial disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4944.html" rel="external">"Recurrent pericarditis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4933.html" rel="external">"Myocarditis: Causes and pathogenesis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4935.html" rel="external">"Treatment and prognosis of myocarditis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/129342.html" rel="external">"COVID-19: Cardiac manifestations in adults", section on 'Myocardial injury'</a>.)</p><p></p><p class="headingAnchor" id="H18607882"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>While the terms myopericarditis and perimyocarditis are often used interchangeably, the terms represent two different disease processes, each with a distinct approach to diagnosis and treatment [<a href="#rid1">1-4</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>"Myopericarditis" refers to cases of confirmed acute pericarditis with elevated troponin but without LV systolic dysfunction. The focus of this topic is myopericarditis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>"Perimyocarditis" refers to cases presenting as acute pericarditis with elevated troponin and LV ejection fraction (LVEF) less than 55 percent. The diagnostic approach to perimyocarditis is the same as for myocarditis [<a href="#rid4">4</a>]. The approach to treatment depends on findings from the diagnostic evaluation but does not intrinsically include treatments common to acute pericarditis and myopericarditis. (See  <a class="medical medical_review" href="/z/d/html/4939.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in adults", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/4935.html" rel="external">"Treatment and prognosis of myocarditis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The causes of myopericarditis are similar to those of acute pericarditis (eg, viral, neoplastic, autoimmune, post-myocardial infarction, postsurgical)  (<a class="graphic graphic_table graphicRef60949" href="/z/d/graphic/60949.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Establishing a definite etiology'</a>.)</p><p>Myopericarditis is a rare complication of smallpox vaccination (vaccinia virus inoculation), as discussed below. (See <a class="local">'Vaccinia-associated myopericarditis'</a> below.)</p><p>Coronavirus 2019 (COVID-19) vaccination is rarely associated with myopericarditis, myocarditis, or pericarditis, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Myocarditis'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The clinical presentation of myopericarditis is similar to the presentation of acute pericarditis (eg, positional and pleuritic chest pain, ECG with new widespread ST elevation or PR depression) [<a href="#rid2">2,5</a>]. (See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Clinical features'</a>.)</p><p>In a study of 254 patients presenting with acute pericarditis, the presence of a pericardial effusion decreased the likelihood of myopericarditis versus isolated acute pericarditis (38 versus 60 percent), while the following presenting features increased the likelihood of myopericarditis [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Younger age (36 years versus 55 years)</p><p class="bulletIndent1"><span class="glyph">●</span>Male sex (75 versus 46 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Recent febrile illness (50 versus 22 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>ST elevation (90 versus 70 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac arrhythmias (predominantly ventricular; 65 versus 17 percent)</p><p></p><p class="headingAnchor" id="H244308266"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H3430676654"><span class="h2">General approach</span><span class="headingEndMark"> — </span>Myopericarditis<em> </em>should be suspected in a patient with confirmed acute pericarditis whose initial testing for chest discomfort reveals a troponin level above the upper reference limit (average troponin I in myopericarditis is 7.2 to 9.4 ng/dL) and normal LV function (eg, portable ultrasound, formal echocardiography)  (<a class="graphic graphic_algorithm graphicRef132075" href="/z/d/graphic/132075.html" rel="external">algorithm 1</a>) [<a href="#rid3">3,6-9</a>]. As noted above, patients with myopericarditis more commonly have ECG changes (mainly widespread or localized ST-segment elevation) compared with those with simple pericarditis. Patients with suspected myopericarditis warrant hospitalization for evaluation and management.</p><p>The diagnosis is confirmed by reasonably excluding other life-threatening causes of elevated troponin (eg, acute coronary syndromes [ACS], acute aortic syndromes, pulmonary embolism):</p><p class="bulletIndent1"><span class="glyph">●</span>We use coronary angiography in patients at intermediate and high risk for ACS to assess for myocardial infarction. (See <a class="local">'When to assess for coronary artery disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We routinely obtain cardiovascular magnetic resonance (CMR) imaging (if available) during the initial presentation or within two weeks of presentation to support the diagnosis of myopericarditis. If CMR imaging is not available, we perform serial echocardiograms to detect further decreases in LV function, which may signal myocarditis. (See <a class="local">'Role of magnetic resonance imaging'</a> below.)</p><p></p><p>If LV systolic function is abnormal (ie, less than 55 percent), the patient is provisionally diagnosed with perimyocarditis, which requires an evaluation for myocarditis [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/4939.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in adults", section on 'Approach to diagnosis of myocarditis'</a>.)</p><p class="headingAnchor" id="H1203906797"><span class="h2">Role of magnetic resonance imaging</span><span class="headingEndMark"> — </span>We obtain CMR imaging with late gadolinium enhancement (LGE) in all patients with suspected myopericarditis to support the diagnosis. CMR imaging is not used to "rule out" ACS [<a href="#rid8">8</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of CMR imaging</strong> –<strong> </strong>CMR imaging is most useful when performed at the initial presentation or within two weeks of symptom onset. CMR imaging should be obtained prior to hospital discharge if perimyocarditis or myocarditis are strongly suspected. If CMR imaging is not immediately available and suspicion for myocarditis is high, additional imaging (eg, repeat echocardiography) may be necessary to manage the patient until CMR imaging is available. (See  <a class="medical medical_review" href="/z/d/html/4939.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in adults", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic CMR image findings</strong> –<strong> </strong>CMR imaging can detect evidence of pericardial and myocardial inflammation and is most specific for myopericarditis in the presence of both edema and inflammation. Myocardial edema is suggested by the presence of global or regional increases in myocardial T2 relaxation time or an increase in mycardial signal intensity in T2-weighted images. Myocardial inflammation is suggested by global or regional increases in myocardial T1, extracellular volume, or LGE. The presence of edema and inflammation increase the specificity for myopericarditis, though a single marker (eg, edema or inflammation) is sufficient to support the diagnosis of myopericarditis. CMR imaging can also detect other features of acute pericarditis (eg, pericardial thickening, pericardial edema, pericardial LGE, and pericardial effusion) that support the diagnosis of myopericarditis [<a href="#rid10">10,11</a>]. (See  <a class="medical medical_review" href="/z/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging", section on 'Pericardial disease'</a>.)</p><p></p><p class="headingAnchor" id="H2500145596"><span class="h2">When to assess for coronary artery disease</span><span class="headingEndMark"> — </span>Coronary angiography should be performed in selected patients with myopericarditis to rule out ACS. We perform coronary angiography (or coronary computed tomography angiography [CCTA], where available) in the presence of one or more of the of the following clinical features:</p><p class="bulletIndent1"><span class="glyph">●</span>History of prior coronary artery disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ECG with possible ischemia (eg, "nonclassical" ECG findings consistent with ischemia).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unstable arrhythmias.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Markedly elevated troponin (eg, troponin I &gt;10 ng/dL) or an acute rise and/or fall pattern.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate to high-risk Global Registry of Acute Coronary Events (GRACE)  (<a class="graphic graphic_table graphicRef88782" href="/z/d/graphic/88782.html" rel="external">table 2</a>) or Thrombolysis in Myocardial Infarction (TIMI)  (<a class="graphic graphic_table graphicRef52542" href="/z/d/graphic/52542.html" rel="external">table 3</a>) score for coronary artery disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistent symptoms despite treatment for myopericarditis.</p><p></p><p>Patients with perimyocarditis (rather than myopericarditis) are evaluated similarly to myocarditis  (<a class="graphic graphic_algorithm graphicRef132075" href="/z/d/graphic/132075.html" rel="external">algorithm 1</a>) [<a href="#rid4">4</a>]; indications for coronary angiography in patients with myopericarditis are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/4939.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in adults", section on 'Cardiac catheterization'</a>.)</p><p>The timing of invasive coronary angiography or CCTA depends entirely on the clinician’s clinical suspicion for an ACS. If the suspicion for an ACS is intermediate or high, we recommend urgent coronary angiography (invasive angiography or CCTA). CCTA may have a role in intermediate-risk patients when CCTA can be rapidly obtained and interpreted. CMR imaging is not a substitute for timely coronary artery evaluation in intermediate- to high-risk patients. (See  <a class="medical medical_review" href="/z/d/html/68.html" rel="external">"Overview of the acute management of non-ST-elevation acute coronary syndromes", section on 'Early risk stratification'</a> and  <a class="medical medical_review" href="/z/d/html/129395.html" rel="external">"Clinical use of coronary computed tomographic angiography"</a>.)</p><p>Studies of myopericarditis note a high use of coronary angiography for evaluation of myopericarditis, though coronary angiography is often negative. As an example, in one retrospective study of 486 patients ultimately diagnosed with either myopericarditis, perimyocarditis, or acute pericarditis, coronary angiography was performed in 76 percent, 76 percent, and 2 percent, respectively [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H3812112031"><span class="h2">Indications for endomyocardial biopsy</span><span class="headingEndMark"> — </span>We rarely perform an endomyocardial biopsy (EMB) in patients with suspected myopericarditis and reserve EMB for complicated cases in which symptoms or signs of heart failure or major arrhythmias develop despite appropriate therapy (eg, suspected complicated perimyocarditis, myocarditis) [<a href="#rid4">4</a>]. Indications for EMB are discussed in detail separately [<a href="#rid12">12,13</a>]. (See  <a class="medical medical_review" href="/z/d/html/4923.html" rel="external">"Endomyocardial biopsy"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Our approach to the treatment of myopericarditis assumes that perimyocarditis, myocarditis, and acute coronary syndrome have been reasonably excluded. Most patients are treated with nonsteroidal antiinflammatory drugs (NSAIDs) and <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>. Inflammatory markers (eg, C-reactive protein) may be more commonly elevated in patients with pericarditis than those with myopericarditis [<a href="#rid9">9</a>]. Patients who do not respond to initial therapy should be reevaluated and the therapeutic regimen should be reconsidered. (See <a class="local">'Diagnostic evaluation'</a> above and  <a class="medical medical_review" href="/z/d/html/4939.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in adults", section on 'When to suspect myocarditis'</a>.)</p><p class="headingAnchor" id="H472648537"><span class="h2">Initial pharmacologic treatment</span><span class="headingEndMark"> — </span>For most patients with acute myopericarditis, we suggest initial therapy with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> combined with NSAIDs rather than NSAIDs alone. In clinical practice, the efficacy of colchicine to prevent additional events is similar to that reported in simple pericarditis.</p><p>We treat myopericarditis with doses typically recommended for acute pericarditis  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 4</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> 500 to 1000 mg three times daily.</p><p></p><p class="bulletIndent1"><strong>OR</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">Ibuprofen</a> 600 to 800 mg three times daily.</p><p></p><p class="bulletIndent1"><strong>OR</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">Indomethacin</a> 25 to 50 mg three times daily is an alternative for those not responding to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>.</p><p></p><p><strong>PLUS</strong></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> 0.5 to 0.6 mg once daily for patients weighing &lt;70 kg.</p><p></p><p class="bulletIndent1"><strong>OR</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> 0.5 to 0.6 mg twice daily for patients weighing ≥70 kg.</p><p></p><p>In most patients, symptoms resolve within 72 hours, at which time NSAIDS are tapered weekly over two to four weeks. <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> is typically continued for three months and then discontinued without tapering the dose. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'NSAID dosing'</a> and  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Colchicine dosing'</a>.)</p><p>Our approach to initial treatment is based on clinical experience and limited observational data in myopericarditis and on the safety and efficacy of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> reported in randomized trials of patients with acute or recurrent pericarditis [<a href="#rid2">2,14,15</a>]. While NSAID therapy is associated with higher mortality in animal models of myocarditis, we do not believe this evidence applies to patients with myopericarditis [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Colchicine'</a> and  <a class="medical medical_review" href="/z/d/html/4944.html" rel="external">"Recurrent pericarditis", section on 'Colchicine'</a>.)</p><p>A preliminary study in an experimental model of viral myocarditis found that <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> reduced markers of myocardial injury (eg, troponin), improved LVEF, and reduced apoptosis and inflammatory markers without impairing the clearance of the viral agent [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H2235269711"><span class="h2">Patients with refractory symptoms and signs</span><span class="headingEndMark"> — </span>If chest symptoms persist beyond 72 hours, cardiac biomarkers remain elevated, and/or LV function decreases, we reevaluate the diagnosis of myopericarditis. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p>If myopericarditis remains the leading diagnosis, patients with intolerance to NSAIDS or <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, or with symptoms refractory to NSAIDs and colchicine, may be treated with a short course of glucocorticoids (after a discussion of the risks and benefits). Beta blockers may be used to treat residual symptoms (eg, palpitations, chest pain). The evidence for the use of glucocorticoids, beta blockers, and other treatments (eg, <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>, <a class="drug drug_general" data-topicid="9483" href="/z/d/drug information/9483.html" rel="external">rilonacept</a>) for treatment of myopericarditis is inferred from observational studies showing a possible benefit in acute or recurrent pericarditis. (See  <a class="medical medical_review" href="/z/d/html/4944.html" rel="external">"Recurrent pericarditis", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H1643007764"><span class="h2">Exercise restriction</span><span class="headingEndMark"> — </span>We counsel complete cessation of competitive sports and limitation of fitness activity to walking and light weight training (not more than 5 kg) for at least three months and until complete clinical remission. For competitive sport activity, a longer restriction time of three to six months may be considered according to individual remission times [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/4935.html" rel="external">"Treatment and prognosis of myocarditis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/986.html" rel="external">"Athletes: Overview of sudden cardiac death risk and sport participation", section on 'Myocarditis'</a>.)</p><p class="headingAnchor" id="H2841343745"><span class="h1">FOLLOW-UP AND PROGNOSIS</span><span class="headingEndMark"> — </span>Given the presence of myocardial injury characteristic of myopericarditis, we routinely perform the following tests within two weeks of discharge:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac troponin</p><p class="bulletIndent1"><span class="glyph">●</span>C-reactive protein (CRP)</p><p class="bulletIndent1"><span class="glyph">●</span>Echocardiography to assess ventricular function</p><p></p><p>Elevated troponin levels usually resolve within days [<a href="#rid9">9</a>]. CRP may rise after the initial presentation, but should decline in response to NSAID therapy [<a href="#rid19">19</a>]. Repeat CMR imaging may be indicated to assess residual myocardial fibrosis in those with initial evidence of myocardial late gadolinium enhancement (LGE). Follow-up CMR should be planned at three to six months. In the acute phase, myocardial LGE may reflect myocardial edema instead of fibrosis as at a later stage (&gt;1 month) when inflammation is relieved and expansion of extracellular space is due to myocardial fibrosis.</p><p>The recurrence of pericardial effusion, pericarditis, and myopericarditis are less frequent than simple pericarditis, and usually occur in 10 to 15 percent of cases [<a href="#rid2">2,9</a>]. In a prospective study that compared 234 patients with presumed viral or idiopathic acute pericarditis with 40 patients with myopericarditis, complication rates (including recurrent myopericarditis and acute pericarditis, cardiac tamponade, and constriction) were similar [<a href="#rid2">2</a>]. At 12 months, echocardiography, ECG, and treadmill testing were normal in 39 of the 40 myopericarditis cases. Similar findings were reported in a larger study that also noted no deaths [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H15"><span class="h1">VACCINIA-ASSOCIATED MYOPERICARDITIS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10175" href="/z/d/drug information/10175.html" rel="external">Smallpox vaccine</a> (vaccinia virus inoculation) is associated with acute pericarditis, myopericarditis, and, rarely, myocarditis [<a href="#rid4">4,12,13</a>]. Vaccinia-associated inflammatory disease is defined as any cardiac inflammatory syndrome occurring within 30 days of vaccination without another identifiable cause [<a href="#rid20">20</a>]. The clinical presentation is similar to that seen with myopericarditis of any etiology, though the intensity of symptoms and severity of disease may be less in vaccinia-associated cases. The incidence and etiology of vaccinia-associated myopericarditis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8296.html" rel="external">"Vaccines to prevent smallpox, mpox (monkeypox), and other orthopoxviruses", section on 'Complications'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – In general, the treatment of vaccinia-associated myopericarditis is similar to that used for myopericarditis of any etiology. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1">Specific guidelines for the management of vaccinia-associated myopericarditis have been outlined by the Department of Defense Vaccine Healthcare Center [<a href="#rid21">21</a>]. According to this algorithm, most symptomatic patients should receive treatment with analgesics and/or NSAIDs, activity restriction for at least four to six weeks, and follow-up assessment in 6 to 12 weeks and again in 6 to 12 months. In vaccinia-associated myopericarditis not responding to NSAID and <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, low to moderate doses of glucocorticoids are efficacious.</p><p></p><p class="bulletIndent1">In patients with progressive symptoms, reduced LVEF, sustained ventricular arrhythmias, or recurrent or persistent troponin release, endomyocardial biopsy should be considered as a guide to therapy [<a href="#rid4">4,12,13</a>] (see  <a class="medical medical_review" href="/z/d/html/4923.html" rel="external">"Endomyocardial biopsy"</a>). Fortunately, this rarely occurs in patients with myopericarditis. If biopsy reveals no active viral infection, the process is likely to be autoimmune; glucocorticoids alone or in association with other immunosuppressive drugs may be beneficial [<a href="#rid2">2,4,12,13</a>]. Active viral infection with vaccinia (as documented by polymerase chain reaction) is a very rare finding on endomyocardial biopsy [<a href="#rid21">21</a>]. If vaccinia infection is present, <a class="drug drug_general" data-topicid="10332" href="/z/d/drug information/10332.html" rel="external">vaccinia immune globulin</a> (VIG) may be effective given its efficacy in treating noncardiac complications of <a class="drug drug_general" data-topicid="10175" href="/z/d/drug information/10175.html" rel="external">smallpox vaccine</a> (see  <a class="medical medical_review" href="/z/d/html/8296.html" rel="external">"Vaccines to prevent smallpox, mpox (monkeypox), and other orthopoxviruses", section on 'Vaccinia immune globulin'</a>). VIG is available from the United States Centers for Disease Control and Prevention on a compassionate use basis (404-639-3670) [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Most patients with vaccinia-associated myopericarditis have mild disease and recover with few short-term effects. On follow-up, functional status, ECG, and echocardiogram normalize in almost all patients [<a href="#rid23">23</a>]. However, up to 13 percent describe atypical, nonlimiting chest discomfort, and fatalities have rarely been reported [<a href="#rid21">21,23</a>].</p><p></p><p class="headingAnchor" id="H2264412519"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116655.html" rel="external">"Society guideline links: Pericardial disease"</a>.)</p><p class="headingAnchor" id="H181486334"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16976.html" rel="external">"Patient education: Pericarditis in adults (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology</strong> – "Myopericarditis" refers to cases of confirmed acute pericarditis with elevated troponin but without left ventricular (LV) systolic dysfunction. "Perimyocarditis" refers to cases presenting as acute pericarditis with elevated troponin and LV ejection fraction (LVEF) less than 55 percent. Myopericarditis is generally evaluated and treated as acute pericarditis, whereas perimyocarditis is evaluated and treated as for myocarditis. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – The causes of myopericarditis are similar to those of acute pericarditis (eg, viral, autoimmune, post-myocardial infarction, postsurgical)  (<a class="graphic graphic_table graphicRef60949" href="/z/d/graphic/60949.html" rel="external">table 1</a>). (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The clinical presentation of myopericarditis is similar to the presentation of acute pericarditis (eg, positional and pleuritic chest pain, ECG with new widespread ST elevation or PR depression), but ECG changes are more common than in cases with simple pericarditis. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – Myopericarditis should be suspected in a patient with confirmed acute pericarditis whose initial testing for chest discomfort reveals a troponin level above the upper reference limit and normal LV function (eg, portable ultrasound, formal echocardiography). The diagnosis is confirmed by reasonably excluding other potentially life-threatening causes of elevated troponin (eg, perimyocarditis, acute coronary syndromes [ACS], myocarditis, pulmonary embolism)  (<a class="graphic graphic_algorithm graphicRef132075" href="/z/d/graphic/132075.html" rel="external">algorithm 1</a>). (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We routinely obtain cardiovascular magnetic resonance (CMR) imaging to support the diagnosis of myopericarditis and to exclude myocarditis (ie, perimyocarditis). If CMR imaging to exclude LV systolic dysfunction is not readily available, we obtain serial echocardiography. (See <a class="local">'Role of magnetic resonance imaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We obtain coronary angiography in intermediate and high-risk patients to assess for myocardial infarction. (See <a class="local">'When to assess for coronary artery disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Our approach to the treatment of myopericarditis assumes that perimyocarditis, myocarditis, and ACS have been reasonably excluded. (See <a class="local">'Initial pharmacologic treatment'</a> above and <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with acute myopericarditis, we suggest initial therapy with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> combined with nonsteroidal antiinflammatory drugs (NSAIDs) rather than NSAIDs alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Initial pharmacologic treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with intolerance to NSAIDS or <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, or with symptoms refractory to NSAIDs and colchicine, may be treated with a short course of glucocorticoids (after a discussion of the risks and benefits). (See <a class="local">'Patients with refractory symptoms and signs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We counsel complete cessation of competitive sports and limitation of fitness activity to walking and light weight training (not more than 5 kg) for at least three to six months. (See <a class="local">'Exercise restriction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elevated troponin levels should resolve in days and months, respectively. C-reactive protein (CRP) may rise after presentation but should decline in response to NSAID therapy. Repeat CMR imaging is not indicated if the patient is recovering clinically, LV morphologic function has improved by echocardiography, and the patient has no myocardial late gadolinium enhancement (LGE) in the first CMR examination. (See <a class="local">'Follow-up and prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinia-associated myopericarditis</strong> – Vaccinia-associated myopericarditis has been defined as myocarditis and/or pericarditis occurring within 30 days after vaccination in the absence of another cause; it is treated the same as myopericarditis unless the disease is severe or refractory, in which case steroids or <a class="drug drug_general" data-topicid="10332" href="/z/d/drug information/10332.html" rel="external">vaccinia immune globulin</a> may be effective. (See <a class="local">'Vaccinia-associated myopericarditis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Spodick DH. Myopericarditis/Perimyocarditis. In: The Pericardium, Marcel Dekker, Inc, New York 2001. p.114.</li><li><a class="nounderline abstract_t">Imazio M, Cecchi E, Demichelis B, et al. Myopericarditis versus viral or idiopathic acute pericarditis. Heart 2008; 94:498.</a></li><li><a class="nounderline abstract_t">Imazio M, Trinchero R. Myopericarditis: Etiology, management, and prognosis. Int J Cardiol 2008; 127:17.</a></li><li><a class="nounderline abstract_t">Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34:2636.</a></li><li><a class="nounderline abstract_t">Imazio M, Demichelis B, Cecchi E, et al. Cardiac troponin I in acute pericarditis. J Am Coll Cardiol 2003; 42:2144.</a></li><li><a class="nounderline abstract_t">Imazio M, Trinchero R. Triage and management of acute pericarditis. Int J Cardiol 2007; 118:286.</a></li><li class="breakAll">Imazio M. Pericarditis associated with myocardial involvement (myopericarditis/perimyocarditis). In: Myopericardial Diseases, Springer International Publishing Switzerland, Cham 2016. p.105.</li><li><a class="nounderline abstract_t">Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36:2921.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Barbieri A, et al. Good prognosis for pericarditis with and without myocardial involvement: results from a multicenter, prospective cohort study. Circulation 2013; 128:42.</a></li><li><a class="nounderline abstract_t">Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol 2018; 72:3158.</a></li><li><a class="nounderline abstract_t">Imazio M, Pivetta E, Palacio Restrepo S, et al. Usefulness of Cardiac Magnetic Resonance for Recurrent Pericarditis. Am J Cardiol 2020; 125:146.</a></li><li><a class="nounderline abstract_t">Seferović PM, Tsutsui H, McNamara DM, et al. Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. Eur J Heart Fail 2021; 23:854.</a></li><li><a class="nounderline abstract_t">Tschöpe C, Ammirati E, Bozkurt B, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol 2021; 18:169.</a></li><li><a class="nounderline abstract_t">Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation 2005; 112:2012.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med 2013; 369:1522.</a></li><li><a class="nounderline abstract_t">Rezkalla S, Khatib G, Khatib R. Coxsackievirus B3 murine myocarditis: deleterious effects of nonsteroidal anti-inflammatory agents. J Lab Clin Med 1986; 107:393.</a></li><li><a class="nounderline abstract_t">Pappritz K, Lin J, El-Shafeey M, et al. Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis. ESC Heart Fail 2022; 9:925.</a></li><li><a class="nounderline abstract_t">Pelliccia A, Solberg EE, Papadakis M, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2019; 40:19.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Maestroni S, et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation 2011; 123:1092.</a></li><li><a class="nounderline abstract_t">Halsell JS, Riddle JR, Atwood JE, et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003; 289:3283.</a></li><li><a class="nounderline abstract_t">Cassimatis DC, Atwood JE, Engler RM, et al. Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 2004; 43:1503.</a></li><li class="breakAll">Information about vaccinia immune globulin available at www.bt.cdc.gov/agent/smallpox/vaccination/vig.asp (Accessed on March 07, 2005).</li><li><a class="nounderline abstract_t">Eckart RE, Love SS, Atwood JE, et al. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J Am Coll Cardiol 2004; 44:201.</a></li></ol></div><div id="topicVersionRevision">Topic 4930 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Spodick DH. Myopericarditis/Perimyocarditis. In: The Pericardium, Marcel Dekker, Inc, New York 2001. p.114.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17575329" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Myopericarditis versus viral or idiopathic acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18221804" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Myopericarditis: Etiology, management, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23824828" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14680742" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cardiac troponin I in acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17049636" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Triage and management of acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17049636" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Triage and management of acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320112" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23709669" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Good prognosis for pericarditis with and without myocardial involvement: results from a multicenter, prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545455" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31711636" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Usefulness of Cardiac Magnetic Resonance for Recurrent Pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34010472" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33046850" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Myocarditis and inflammatory cardiomyopathy: current evidence and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186437" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23992557" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A randomized trial of colchicine for acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2420912" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Coxsackievirus B3 murine myocarditis: deleterious effects of nonsteroidal anti-inflammatory agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35178861" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30561613" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21357824" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12824210" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15120802" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Smallpox vaccination and myopericarditis: a clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15120802" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Smallpox vaccination and myopericarditis: a clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15234435" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
